Recruiting Trials

Recruiting Trials are clinical trials that are fully approved and accepting patients. Please click on the links below for further information about trials currently accepting patients.

01.10 CARPETS 
02.12 RADICAL 
01.15 CHARLI 
04.17 SMARTI 
09.17 PRIME002 
10.17 GoTHAM 
02.18 MelMarT-II 
03.18 I-MAT
02.19 IMAGE

01.10 CARPETS

Phase I study of safety and immune effects of an escalating dose of autologous GD2 chimeric antigen receptor-expressing peripheral blood T cells in patients with metastatic melanoma

Chair

Professor Michael Brown

Registration ID

ACTRN12613000198729

Trial Status

Recruiting Trial

MASC Trials Contact

hello@masc.org.au

02.12 RADICAL

A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused, or fails

Chair

Associate Professor Pascale Guitera

Registration ID

ACTRN12615000266561

Trial Status

Recruiting Trial

MASC Trials Contact

radical@masc.org.au

01.15 CHARLI

A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients with Unresectable Stage III and IV Melanoma

Chair

Associate Professor Shahneen Sandhu

Registration ID

ACTRN12617000772347

Trial Status

Recruiting Trial

MASC Trials Contact

charli@masc.org.au

04.17 SMARTI

A Pilot Study of an Artificial Intelligence System as a Diagnostic Aide for Better Skin Cancer Management

Chair

Associate Professor Victoria Mar

Registration ID

NCT04040114

Trial Status

Recruiting Trial

MASC Trials Contact

smarti@masc.org.au

09.17 PRIME002

Early Phase II Study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy

Chair

Dr Andre van der Westhuizen

Registration ID

ACTRN12618000053224

Trial Status

Recruiting Trial

MASC Trials Contact

hello@masc.org.au

10.17 GoTHAM

A Phase Ib/II study of combination avelumab with peptide receptor radionuclide therapy or conventional fractioned radiotherapy in patients with metastatic Merkel cell carcinoma

Chair

Associate Professor Shahneen Sandhu

Registration ID

NCT04261855

Trial Status

Recruiting Trial

MASC Trials Contact

gotham@masc.org.au

02.18 MelMarT-II

A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma

Chair

Professor Michael Henderson and Professor Marc Moncrieff

Registration ID

NCT03860883

Trial Status

Recruiting Trial

MASC Trials Contact

melmart@masc.org.au

03.18 I-MAT

A randomised, placebo-controlled, Phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma

Chair

Dr Wen Xu

Registration ID

NCT04291885

Trial Status

Recruiting Trial

MASC Trials Contact

imat@masc.org.au

Further information

To learn more about the I-MAT clinical trial, which aims to improve the management of early stage Merkel Cell Carcinoma, click here. This discussion between Dr Wen Xu (Study Chair), Professor Gerald Fogarty (Chair of AMIGOs) and Jonathan Pincus (Merkel Cell Carcinoma Patient) highlights just why this trial is so vital.

02.19 IMAGE

Melanoma Surveillance Photography to improve early detection of melanoma in very high risk (or high risk) patients

Chair

Associate Professor Victoria Mar

Registration ID

NCT04385732

Trial Status

Recruiting Trial

MASC Trials Contact

image@masc.org.au